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BACKGROUND: Primary results of this prospective, open-label, multicenter trial suggested that alcohol-mediated renal 
denervation with perivascular injection of dehydrated alcohol using the Peregrine System Infusion Catheter safely reduces 
blood pressure (BP) in patients with resistant hypertension. To date, maintenance of the BP-lowering effect beyond 6 
months using this novel technology has not been reported. This article describes the final, 12-month follow-up data on the 
safety and efficacy of alcohol-mediated renal denervation in these patients.
METHODS: Forty-five patients with resistant hypertension on a stable regimen of on average 5.1±1.5 antihypertensive 
medications underwent successful bilateral renal denervation using the Peregrine Catheter with alcohol as the neurolytic 
agent (0.6 mL per renal artery). Apart from 2 vascular access pseudoaneurysms (both without sequelae), no major procedural 
complications occurred.
RESULTS: At 12 months post-procedure, mean 24-hour ambulatory systolic and diastolic BP were reduced by 10 mm Hg (95% CI, 
−16 to −5) and 7 mm Hg (−10 to −3), respectively (P<0.001). Office systolic/diastolic BP was reduced by 20/10 mm Hg (−27, 
−13/−14, −6; <0.001). Compared with baseline, the number of antihypertensive medications was reduced in 21% of patients, 
while it was increased in 19%. From baseline to 12 months, serum creatinine, urea, cystatin C, and spot urine albumin levels 
remained unchanged. The change in estimated glomerular filtration rates (−3.9±10.3 mL/minute per 1.73 m2 [95% CI, −7.1 to 
−0.75]; P=0.02) was within the expected range. There were no cases of renal artery stenosis up to 12-month follow-up.
CONCLUSIONS: Catheter-based chemical renal denervation with dehydrated alcohol using the Peregrine Catheter seems to 
safely reduce BP at follow-up of up to 12 months. Further randomized and sham controlled studies are underway to further 
validate these findings.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02570113.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
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Renal sympathetic nerves play a crucial role in blood pressure (BP) regulation. Increased sympathetic activity is an important contributor to elevated BP 
in many patients.1 Accordingly, modulating sympathetic 
nerve activity at the level of the kidneys is under inves-
tigation as a therapeutic approach for the treatment 
of hypertension.2,3 Catheter-based renal denervation 
(RDN) may represent a potential therapeutic approach, 
alone or as an adjunctive intervention, combined with 
lifestyle modification and appropriate medical therapy, 
to treat resistant hypertension.4 Different approaches, 
using various catheters, have been developed such as 
thermal ablation using radiofrequency5,6 and ultrasound.7 
An alternative approach is to perform alcohol-mediated 
RDN using the 3 needle-based delivery device (Pere-
grine Catheter, Ablative Solutions, Inc, San Jose, CA).8 
Alcohol delivered through the Peregrine Catheter had 
been evaluated in preclinical models, showing a radial 
diffusion of alcohol into the treatment zones and neuroly-
sis at depths of ≈8 mm from the intimal surface, depend-
ing on the local anatomy.9,10
This international, multicenter, feasibility trial was 
designed to provide clinical data to evaluate the safety 
and efficacy of chemical RDN using the Peregrine 
Catheter. The primary 6-month results of this trial dem-
onstrated both reductions in 24-hour ambulatory, and 
office-measured BP, with an acceptable safety pro-
file.11 The longer-term safety and BP-lowering effect 
of alcohol-mediated RDN has not been previously 
reported. Accordingly, the objective of the present final 
analysis was to examine the 12-month safety and BP-
lowering efficacy of chemical RDN with the injection 
of 0.6 mL of alcohol per renal artery in patients with 
resistant hypertension.
METHODS
The data of this study are available from the corresponding 
author on reasonable request. The prospective, single-arm, 
open-label trial design and methodology, including the clinical 
and laboratory assessments and imaging performed and the 
RDN procedure, have been described previously.11 The trial 
was approved by the ethics committees of all 9 participating 
centers in Europe (located in Poland, Czech Republic, Belgium, 
and Germany), and, if applicable, by the relevant Competent 
Authorities and conducted in accordance with the Declaration 
of Helsinki. Between January 28, 2016 and March 26, 2018, 
45 patients were treated with the RDN procedure with con-
secutive 12 months follow-up. All patients provided written 
informed consent to complete up to 12 months follow-up.
Study Population and Procedures
To be eligible, patients were required to have a mean office-
based BP of at least 150/85 mm Hg, with an accompany-
ing 24-hour ambulatory systolic BP of 135 mm Hg or higher, 
despite treatment with at least 3 antihypertensive drug classes 
including a diuretic, thereby meeting the criteria for resistant 
hypertension.12 Inclusion also required patients to have a renal 
artery diameter of ≥4 and ≤7 mm, a main renal artery length of 
≥5 mm, and to be >18 years of age. Patients were not eligible 
if they had type 1 diabetes, severe untreated obstructive sleep 
apnea, nephrotic syndrome, an estimated glomerular filtration 
rate (eGFR) of ≤20 mL/minute per 1.73 m2, or a history of 
cardiovascular or cerebrovascular events. Patients with renal 
artery stenosis, or one or more accessory arteries that were too 
small to be treated, as assessed by magnetic resonance angi-
ography (N=26), computed tomographic angiography (N=18) 
and (quantitative) renal angiography (N=1), were excluded.
After a stable antihypertensive medication regimen of 
at least 4 weeks, 45 eligible patients with mean office BP 
of 169/99±15/13 mm Hg, corresponding 24-hour mean 
ambulatory BP of 151/89±14/12 mm Hg, and with suitable 
renal arterial anatomy evaluated with a preprocedural renal 
duplex ultrasound (RDUS) and computed tomographic angi-
ography/magnetic resonance angiography, underwent bilat-
eral RDN (of each of the 2 renal arteries). Four patients each 
had 1 accessory renal artery treated in addition to the 2 main 
renal arteries, and one patient had 2 procedures staged for 
Nonstandard Abbreviations and Acronyms
BP blood pressure
eGFR estimated glomerular filtration rate
RDN renal denervation
RDUS renal duplex ultrasound
WHAT IS KNOWN
• Modulating renal sympathetic nerve activity through 
catheter-based renal denervation is under investi-
gation as a potential therapeutic approach for the 
treatment of resistant hypertension.
• Injection of dehydrated alcohol around the kidney 
artery using the Peregrine Catheter represents a 
novel approach for renal nerve ablation.
WHAT THE STUDY ADDS
• This is the first prospective trial evaluating the main-
tenance of safety and blood pressure-lowering 
effect up to 12 months after using chemical renal 
denervation with the Peregrine Catheter in patients 
with resistant hypertension.
• Findings from this trial highlight that catheter-based 
alcohol-mediated renal denervation appears to 
cause a significant blood pressure reduction that 
was maintained at 12 months.
• There were no renal artery stenoses or other major 
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unilateral treatment of each renal artery. Therefore, a total of 
94 renal arteries were treated using the Peregrine Catheter 
with 0.6 mL of alcohol infused per renal artery and with a 
mean (SD) distance from the ostium to the infusion site of 
20.2 (6.6) mm. All 46 procedures were technically successful 
without device deficiencies, with a mean treatment time of 
7±3 minute/artery (Table I in the Data Supplement). No gen-
eral anesthesia and minimal conscious sedation was given. 
Mild or no pain was reported during alcohol infusion in 50/87 
(57%) renal arteries for which periprocedural pain data were 
obtained. There were 2 vascular access pseudoaneurysms, 
both without longer-term sequelae. The patients were seen 
at scheduled visits at 7 days, 1 month, and 3, 6, and 12 
months. At the 12-month visit, patients came to the study 
center to undergo seated office BP measurements (triplicate 
readings), RDUS, a physical exam and laboratory assess-
ments, and to record adverse events and antihypertensive 
medications. Seated office BP was measured with the same 
validated device (Omron 705IT with printer, Omron, Kyoto, 
Japan) in all patients, as described previously.11 Sequential 
24-hour ambulatory BP measurements were recorded to 
assess eligibility at baseline, after the 4-week stable regimen 
of antihypertensive medications and at 1, 3, 6 and 12 months 
post-procedure (Spacelabs Healthcare Monitor, Spacelabs 
Healthcare, Snoqualmie, Washington), as described previ-
ously.11 All 24-hour ambulatory BP readings were sent to a 
core laboratory (ERT, St. Louis, MO). Renal artery imaging 
by RDUS, computed tomographic angiography or magnetic 
resonance angiography was performed at baseline, and at 
6 and 12 months to detect renal artery stenosis; images 
were assessed by a core laboratory (Cardiovascular Core 
Analysis Laboratory, Stanford University, Stanford, California), 
as described previously.11 The trial is registered at www.
ClinicalTrials.gov, NCT02570113.
End Points
Primary end points previously reported were the absence of 
any periprocedural major vascular complications, major bleed-
ing as defined by the Thrombolysis in Myocardial Infarction 
bleeding classification, acute kidney injury, or death within 1 
month of the procedure, and reduction of 24-hour ambula-
tory systolic BP at 6 months versus baseline.11 Final follow-up 
occurred at 12 months. Secondary efficacy end points were 
changes in office BP, ambulatory BP monitoring results (day-
time and nighttime), antihypertensive medications, and renal 
function as evaluated using laboratory parameters (eGFR, 
serum creatinine, cystatin C, albuminuria, and albuminuria 
categorization).
In addition, major and serious adverse events reported by 
the study centers up to 12 months post-procedure were sent 
for review and adjudication by an independent clinical events 
committee.11
Statistical Analysis
This trial was not powered for formal hypothesis testing. Data 
were summarized using descriptive statistics.11 To describe 
continuous variables, the mean±SD were used (or medians 
and percentiles of the interquartile range when non-normally 
distributed), and for categorical variables, frequencies, and per-
centages. The last value collected before the procedure repre-
sented the baseline value. For binary and continuous variables, 
CIs were estimated using exact binomial methods and the nor-
mal approximation, respectively. Univariate logistic regression 
analysis of key demographic, medical history and renal artery 
characteristics with 24-hour ambulatory systolic BP response 
was performed. P of ≤0.05 were considered statistically sig-
nificant without adjustment for multiplicity. All analyses were 
Figure 1. Schematic of the flow of patient enrollment and follow-up.
Flow diagram showing the flow of patients in the clinical trial through the selection process, treatment, and follow-up. *One patient returned for 
the 12-mo visit but was unable to complete efficacy assessments due to an adverse event (cerebrovascular accident). Note that the number 
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performed using statistical analysis system (SAS) software, 
Version 9.4 (SAS Institute, Cary, NC).
RESULTS
Study Population
After undergoing a 4-week run-in period not allowing 
changes in antihypertensive medications, 45 patients 
were treated. At the 12-month timepoint, 41 patients 
completed the trial. Three patients withdrew consent, and 
1 patient was unable to complete efficacy assessments 
at the 12-month visit due to a stroke (Figure 1).
Baseline characteristics including demographics, med-
ical history, and antihypertensive medications are listed 
in Table 1, as reported previously.11 At the time of enroll-
ment, patients took on average 5.1±1.5 antihypertensive 
medications, with the majority of patients taking diuretics 
(44/45, 98%), calcium channel blockers (38/45, 84%), 
beta blockers (34/45, 76%), and angiotensin recep-
tor blockers (33/45, 73%). A total of 47% (21/45) of 
patients took a mineralocorticoid receptor antagonist.
Overall, 26 patients underwent magnetic resonance 
angiography and 18 patients underwent computed 
tomographic angiography at baseline. Forty-three out of 
45 patients underwent RDUS at baseline.
Efficacy
The significant reduction in 24-hour ambulatory systolic 
and diastolic BP that was seen 1, 3, and 6 months after 
the procedure persisted at 12 months (Table 2, Figure 2). 
At all timepoints after the procedure including 12-month 
follow-up, both 24-hour ambulatory and office systolic 
and diastolic BP were significantly lower than baseline 
BP (P<0.001). The proportion of patients with a decrease 
in 24-hour ambulatory systolic BP from baseline to 12 
months of at least 5 or 10 mm Hg was 61% (23/38) 
and 47% (18/38), respectively. At 12 months post-pro-
cedure, mean daytime ambulatory systolic and diastolic 
BP (95% CI) showed larger reductions (−12/−8 mm Hg 
[−17, −6/−12, −4]) than mean nighttime ambulatory 
systolic and diastolic BP (−8/−5 mm Hg [−15, −2/−9, 
−2]) (Figure 3). At 12 months post-procedure, decreases 
of at least 5 and 10 mm Hg in office systolic BP were 
recorded in 76% (31/41) and 71% (29/41) of patients, 
respectively (Table 2). A total of 13 out of 41 patients 
(32%) had controlled BP at 12 months (defined as office 
BP <140/90 mm Hg). Hourly ambulatory systolic and 
diastolic BP are presented at baseline and at 6, and 12 
months in Figure 4. These ambulatory readings indicate 
continued BP reduction at all timepoints throughout the 
24-hour period, a phenomenon that has been previously 
described as always on.13
The number of antihypertensive medications at 12 
months of follow-up was unchanged as compared with 
baseline (−0.1±1.4 [95% CI, −0.5 to 0.4]). In addition, 
types of antihypertensive medications being taken at 
12 months of follow-up were similar to baseline. Nine 
patients (21%) were on a reduced number of medica-
tions at 12 months compared with baseline; 8 (19%) 
were on an increased number of medications.
Univariate analysis of key preprocedure characteris-
tics identified no strong independent predictor of treat-
ment effect at 12 months (see Data Supplement).
Renal Function
Paired baseline and 12-month follow-up renal function 
parameter data were available for 41 patients. Serum 
creatinine and urea levels remained stable (0.92±0.19 
[N=45] to 0.96±0.19 mg/dL [N=41], P=0.06; and 








eGFR (CKD-EPI formula), mL/min per 1.73 m2 85±16
Chronic kidney disease (eGFR <60 mL/min per 1.73 m2) 2%
Type 2 diabetes 33%
Hyperlipidemia 49%
Coronary artery disease 9%
Peripheral artery disease 7%
Smoking (ever) 42%
Isolated systolic hypertension* 4%
Heart failure 4%
Prior myocardial infarction 4%
Cerebrovascular accident/transient ischemic attack 7%
Office systolic/diastolic BP, mm Hg 169/99±15/13
24-h ambulatory systolic/diastolic BP, mm Hg 151/89±14/12
Mean number of antihypertensive medications 5.1±1.5
Medication class
 ACE inhibitor 29%
 Angiotensin 2 receptor blocker 73%
 Calcium channel blocker 84%
 Diuretics 98%
  Spironolactone 47%
 β-blocker 76%
 Centrally acting alpha agonist 44%
 Direct acting vasodilator 29%
 Renin inhibitor 4%
 Other 9%
Data are percentages or mean±SD. ACE indicates angiotensin-converting 
enzyme; BMI, body mass index; BP, blood pressure; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration; and eGFR, estimated glomerular filtra-
tion rate.
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33.84±10.33 to 36.71±14.44 mg/dL, P=0.34). Cystatin 
C levels remained unchanged through 12-month follow-
up (0.98±0.19 to 0.98±0.21 mg/L, P=0.67). Estimated 
GFR levels decreased from baseline to 12 months 
(85±16 to 80±17 mL/minute per 1.73 m2, P=0.02) and 
were within the expected range in patients with resistant 
hypertension. No patient showed a clinically significant 
reduction in eGFR (as assessed by the investigator) 
after baseline through 12 months. Two patients had a 
reduction in eGFR of >25% between baseline and the 
12-month follow-up visit. The first patient had normal 
eGFR values at 7 days, 1 month, and 3 months but a 
>25% drop at 6 months, as previously reported,11 which 
improved but did not return to baseline values at the 
12-month visit. For the other patient, the eGFR values 
decreased gradually throughout the trial (69.3–50.7 mL/
minute per 1.73 m2 from baseline to 12 months). Spot 
urine albumin levels remained stable up to 6 months11 
and even decreased at the 12-month visit (20±75 to 
12±32 mg/dL, P=0.25). Albuminuria categorization 
remained normal to mild (albumin to creatinine ratio <30) 
in all patients at 12 months follow-up.
Vascular and Overall Safety
At 6 months, no renal artery stenoses were identified.11 
Long-term follow-up imaging by RDUS 12 months 
post-procedure showed no evidence of new renal 
artery stenosis or other anatomic abnormalities. Up to 
12-months, 2 patients had events adjudicated as major 
vascular complications, both occurring peri-interventional 
(vascular access site/femoral artery pseudoaneurysm), 
and 1 patient had hypotension due to vasovagal stimu-
lation related to pain during the infusion, as described 
previously.11
DISCUSSION
Final data from this feasibility trial have shown that the 
initially reported ambulatory and office BP reductions 
at 6 months after chemical RDN using the Peregrine 
Catheter are maintained at 12 months post-procedure. 
The persistent BP reduction at a clinically relevant mag-
nitude occurred in patients who suffered from resistant 
hypertension while on multiple medications. Reductions 
of at least 5 mm Hg in office systolic BP were recorded 
in 76% of patients at 12 months. Moreover, in patients 
treated with alcohol-mediated RDN followed for 12 
months, the procedure was safe and well tolerated with 
no significant late adverse events.
The office BP lowering associated with RDN at 12 
months was 20/10 mm Hg. Although only a minority of 
patients were controlled to the 2017 American College 
of Cardiology and American Heart Association recom-
mended targets of <130/80 mm Hg,14 it is reasonable to 
suggest that RDN may beneficially impact cardiovascular 
Table 2.  Efficacy Assessment—Ambulatory and Office Blood Pressure
 
Mean 24-h ambulatory blood pressure
Systolic Diastolic
1 mo 3 mo 6 mo 12 mo 1 mo 3 mo 6 mo 12 mo
N=42 N=36 N=42 N=38 N=42 N=36 N=42 N=38
Matched baseline, mm Hg, 
mean±SD
150±13 150±13 151±14 149±12 88±11 88±11 89±12 88±11
Blood pressure, mm Hg, mean±SD 141±15 140±15 140±16 139±17 82±11 81±10 83±12 81±11


















 P Value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
 ≥5 mm Hg, % 64% 67% 71% 61% 52% 56% 69% 47%
 ≥10 mm Hg, % 45% 42% 52% 47% 21% 25% 24% 32%
 Office blood pressure
Systolic Diastolic
1 mo 3 mo 6 mo 12 mo 1 mo 3 mo 6 mo 12 mo
N=45 N=43 N=44 N=41 N=45 N=43 N=44 N=41
Matched baseline, mm Hg, 
mean±SD
169±15 169±15 169±15 169±15 99±13 99±13 99±13 99±13
Blood pressure, mm Hg, mean±SD 151±19 152±20 151±21 149±23 90±14 91±14 90±14 89±14


















 P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
 ≥5 mm Hg, % 78% 67% 70% 76% 73% 63% 70% 66%
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outcomes in this challenging patient population. Based 
on trial data with antihypertensive drugs, an effect size 
of 20 mm Hg on office systolic BP should confer 54% 
relative risk reduction in stroke, 56% in heart failure, and 
26% in all-cause mortality.15
The extent of BP lowering at 12 months post-pro-
cedure is very similar to that observed at 6 months: 
−10/−7 mm Hg (−16, −5/−10, −3) versus −11/−7 
mm Hg (−15, −7/−9, −4), respectively, for ambulatory 
BP and −20/−10 mm Hg (−27, −13/−14, −6) versus 
−18/−10 mm Hg (−25, −12/−13, −6) for office BP. 
Similar to radiofrequency-based RDN,16,17 these results 
suggest that the BP-lowering effects of RDN are per-
sistent, at least to 12 months, and that functional rein-
nervation may not occur post-procedure during this time 
interval. The longer-term effects, beyond 12 months, 
requires further evaluation in the ongoing randomized tri-
als.18 Furthermore, hourly ambulatory BP measurements 
demonstrate that the BP-lowering effect is maintained 
at all times over the circadian cycle (always on). This 
effect is maintained throughout 12 months of follow-up 
(Figure 4).
Resistant hypertension is an important contributor to 
the deterioration in renal function and lowering the BP 
could have renal protective effects. Overall, renal func-
tion laboratory parameters remained stable throughout 
the trial showing no substantial decline of renal function. 
Although no meaningful conclusions can be drawn from 
the slight decrease in eGFR at 12 months, the reduc-
tions in eGFR are within the expected range for hyper-
tensive patients.8,16,19 None of the individual changes 
were judged to be clinically meaningful by the investiga-
tor. It is also accepted that kidney function decreases 
in hypertensive patients with advancing patient age.20 In 
addition, the reported P of 0.02 should be interpreted 
with caution due to the lack of Type I error control. There-
fore, CIs were reported to provide an assessment of 
the strength of the estimated effect (−7.1 to −0.75). In 
the RADIANCE SOLO trial, a small increase in eGFR 
was observed in the RDN group (N=69) at 6 months 
(84.2±15.7 to 86.9±16.7 mL/minute per 1.73 m2).7 
Comparable results were seen in the first small trials 
assessing chemical RDN with the Peregrine catheter 
and alcohol: 66±16 to 75±13 mL/minute per 1.73 m2 
Figure 2. Ambulatory and office blood 
pressure results at 1-, 3-, 6-, and 12-mo 
follow-up.
Mean reductions in (A) 24-h ambulatory 
systolic blood pressure (ASBP) and 
diastolic blood pressure over time and (B) 
office systolic blood pressure (OSBP) and 
diastolic blood pressure over time. Note: all 
differences from baseline were statistically 
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(N=16) at 6 months8 and 78±21 to 80±20, 77±20 and 
85±14 mL/minute per 1.73 m2 at 6 months (N=10), 12 
months (N=10), and 24 months (N=8), respectively.19
Another important observation from this extended 
follow-up of alcohol-mediated RDN was the sustained 
safety. After this longer period of post-procedure fol-
low-up, there were no safety signals. In particular, renal 
artery imaging at 12 months showed no new renal artery 
stenosis.
Limitations
Because of the limited power of the present trial and 
the small patient population, univariate analysis was per-
formed to determine independent predictors of future 
BP reduction. In line with other studies,18 no robust pre-
dictor has been identified.
This was an open-label study without a sham control. 
Therefore, the Hawthorne effect and other patient- and 
physician-related biases should be considered when 
interpreting these exploratory results.21 This limitation will 
be addressed in 2 ongoing, sham-controlled, randomized, 
blinded clinical trials also using alcohol-mediated RDN 
(TARGET BP OFF-MED [NCT03503773] and TAR-
GET BP I [NCT02910414]) in which similar patients are 
recruited and randomly assigned to RDN or a sham pro-
cedure.22 Additionally, the longer-term follow-up of BP 
response and safety and larger sample size in these 2 
sham-controlled trials will provide more confident infor-
mation on vascular and overall safety and allow excluding 
rare adverse events.
Perspectives
The BP-lowering effect of chemical RDN with dehy-
drated alcohol using the Peregrine Catheter was main-
tained through 12 months. Throughout this follow-up 
period, no major safety signals with regards to renal 
function or renal vascular safety emerged. If efficacy and 
safety is sustained in the larger, ongoing, randomized, 
sham-controlled studies, alcohol-mediated RDN could 
prove to be a promising treatment for patients with resis-
tant hypertension.
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